Bupivacaine hydrochloride is under clinical development by OncoZenge and currently in Phase II for Oral Mucositis. According to GlobalData, Phase II drugs for Oral Mucositis does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Bupivacaine hydrochloride LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Bupivacaine hydrochloride overview
Bupivacaine hydrochloride is under development for the treatment of oral mucositis. The drug candidate is administered through oral route as a lozenge. It targets prostanoid EP1 receptor and sodium channel.
It was under development for the treatment of chronic pain in burning mouth syndrome, Sjogren's syndrome, and Lichen planus.
OncoZenge overview
OncoZenge operates within the pharmaceuticals and healthcare industry, specifically focusing on the therapy area of central nervous system pain. It specializes in developing and manufacturing treatments for pain management. The company is headquartered in Bromma, Stockholm, Sweden.
For a complete picture of Bupivacaine hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
